0001209191-15-054225.txt : 20150617 0001209191-15-054225.hdr.sgml : 20150617 20150617170124 ACCESSION NUMBER: 0001209191-15-054225 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150615 FILED AS OF DATE: 20150617 DATE AS OF CHANGE: 20150617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: China Biologic Products, Inc. CENTRAL INDEX KEY: 0001369868 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 752308816 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 18TH FL, JIALONG INTERNATIONALBUILDING STREET 2: 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100125 BUSINESS PHONE: 86-10-6598-3111 MAIL ADDRESS: STREET 1: 18TH FL, JIALONG INTERNATIONALBUILDING STREET 2: 19 CHAOYANG PARK ROAD, CHAOYANG DISTRICT CITY: BEIJING STATE: F4 ZIP: 100125 FORMER COMPANY: FORMER CONFORMED NAME: GRC Holdings, Inc. DATE OF NAME CHANGE: 20060721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WP X Biologics LLC CENTRAL INDEX KEY: 0001575882 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34566 FILM NUMBER: 15937715 BUSINESS ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: X1 ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: X1 ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAYE CHARLES R CENTRAL INDEX KEY: 0001239318 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34566 FILM NUMBER: 15937716 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Landy Joseph P. CENTRAL INDEX KEY: 0001220638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34566 FILM NUMBER: 15937717 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER NAME: FORMER CONFORMED NAME: LANDY JOSEPH DATE OF NAME CHANGE: 20030225 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-06-15 0 0001369868 China Biologic Products, Inc. CBPO 0001575882 WP X Biologics LLC C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001239318 KAYE CHARLES R C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001220638 Landy Joseph P. C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 Common Stock 2015-06-15 4 S 0 2645000 100.275 D 8344200 D The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain underwriting agreement dated June 10, 2015 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds") and Morgan Stanley & Co. International plc, Credit Suisse Securities (USA) LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Jefferies LLC as representatives to the underwriters named in the Underwriting Agreement (collectively, the "Underwriters"). At the closing of the transaction contemplated under the Underwriting Agreement on June 15, 2015, the Funds sold an aggregate of 2,645,000 shares of Common Stock to the Underwriters for a purchase price of $265,227,375.00, or $100.275 per share. As of June 15, 2015, WP X Biologics LLC, a Delaware limited liability company ("WP X B"), is the holder of an aggregate of 3,112,920 shares of Common Stock of the Issuer. WP X B is owned 96.9% by WP X and 3.1% by WPP X, and therefore, WP X may be deemed to beneficially own 8,085,529 shares of Common Stock, including 5,069,110 shares that it directly holds and WPP X may be deemed to beneficially own 258,671 shares of Common Stock, including 162,170 shares that it directly holds. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), and the general partner of WP X GP, (Continued from footnote 2) Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company ("WP"), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC"), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a "Warburg Pincus Reporting Person" and collectively, the "Warburg Pincus Reporting Persons") may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer held by the Funds and WP X B. Messrs. Kaye and Landy may be deemed to control WP X B, the Funds, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC. Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Person, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than WP X B and the Funds, herein states that this Form 4 shall not be deemed an admission that it or he is the beneficial owner of any of the shares of Common Stock of the Issuer reported in this Form 4. Each of WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock of the Issuer, except to the extent of its or his pecuniary interest in such shares of Common Stock. Solely for the purposes of Section 16 of the Exchange Act, each of the Funds, WP X B, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, and WP may be deemed a director-by-deputization by virtue of the presence of their representatives on the board of directors of the Issuer. * The Power of Attorney given by each of Mr. Kaye and Mr. Landy was previously filed with the U.S. Securities & Exchange Commission on November 26, 2013 as an exhibit to a statement on a Form 4 filed by Warburg Pincus Private Equity IX, L.P. with respect to Laredo Petroleum Holdings, Inc. and is hereby incorporated by reference. Form 2 of 2. /s/ Robert B. Knauss, Attorney-in-Fact* 2015-06-17